drugset / Trial / NCT02993029

99Tc-MDP Treatment for Knee Osteoarthritis

NCT02993029

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.

Timeline

Start
2017-09-01
Primary completion
2027-12-30
Completion
2027-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 99Tc-MDP Unknown 15 mg Intravenous
Comparator Celecoxib Other / unclassified 200 mg Oral

Indications

No indication recorded.